Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1799 1
1945 1
1950 1
1951 3
1953 2
1954 2
1955 1
1956 2
1957 2
1958 1
1960 3
1961 1
1962 5
1963 8
1964 9
1965 5
1966 6
1967 4
1968 10
1969 8
1970 8
1971 5
1972 6
1973 9
1974 9
1975 17
1976 9
1977 12
1978 12
1979 12
1980 11
1981 16
1982 13
1983 20
1984 29
1985 29
1986 31
1987 41
1988 37
1989 51
1990 52
1991 66
1992 64
1993 57
1994 60
1995 71
1996 87
1997 87
1998 96
1999 142
2000 193
2001 254
2002 268
2003 337
2004 394
2005 473
2006 573
2007 622
2008 645
2009 766
2010 809
2011 1071
2012 1109
2013 1239
2014 1462
2015 1700
2016 1765
2017 1803
2018 1972
2019 2256
2020 2158
2021 13
Text availability
Article attribute
Article type
Publication date

Search Results

20,645 results
Results by year
Filters applied: . Clear all The following term was not found in PubMed: Jaechoon
Page 1
Japan's healthcare policy for the elderly through the concepts of self-help (Ji-jo), mutual aid (Go-jo), social solidarity care (Kyo-jo), and governmental care (Ko-jo).
Sudo K, Kobayashi J, Noda S, Fukuda Y, Takahashi K. Sudo K, et al. Biosci Trends. 2018 Mar 18;12(1):7-11. doi: 10.5582/bst.2017.01271. Epub 2018 Feb 26. Biosci Trends. 2018. PMID: 29479017 Free article.
The Japanese government, therefore, is seeking to implement "The Community-based Integrated Care System" with the aim of building comprehensive up-to-the-end-of-life support services in each community. The system has four proposed elements: self-help (Ji-jo), mutual aid (G …
The Japanese government, therefore, is seeking to implement "The Community-based Integrated Care System" with the aim of building comprehens …
Clinical spectrum of anti-Jo-1-associated disease.
Monti S, Montecucco C, Cavagna L. Monti S, et al. Curr Opin Rheumatol. 2017 Nov;29(6):612-617. doi: 10.1097/BOR.0000000000000434. Curr Opin Rheumatol. 2017. PMID: 28796005 Review.
PURPOSE OF REVIEW: To provide the most recent evidence on anti-Jo-1 syndrome. RECENT FINDINGS: Several new evidences on anti-Jo-1 syndrome have recently emerged. ...SUMMARY: Recent evidence has shed a light on the need for a better understanding of the clinical cour …
PURPOSE OF REVIEW: To provide the most recent evidence on anti-Jo-1 syndrome. RECENT FINDINGS: Several new evidences on anti-Jo
Introduction.
Jo V. Jo V. Semin Diagn Pathol. 2019 Mar;36(2):83-84. doi: 10.1053/j.semdp.2019.02.002. Epub 2019 Feb 28. Semin Diagn Pathol. 2019. PMID: 30852047 No abstract available.
Role of Jo-1 in the Immunopathogenesis of the Anti-synthetase Syndrome.
Ascherman DP. Ascherman DP. Curr Rheumatol Rep. 2015 Sep;17(9):56. doi: 10.1007/s11926-015-0532-1. Curr Rheumatol Rep. 2015. PMID: 26210509 Review.
Histidyl-tRNA synthetase (HRS = Jo-1) represents a key autoantibody target in the anti-synthetase syndrome that is marked by myositis as well as extra-muscular organ complications including interstitial lung disease (ILD). ...Combining these facets of Jo-1-mediated …
Histidyl-tRNA synthetase (HRS = Jo-1) represents a key autoantibody target in the anti-synthetase syndrome that is marked by myositis …
Anti-Jo-1 Syndrome Often Misdiagnosed as Rheumatoid Arthritis (for Many Years): A Single-Center Experience.
Kumar RR, Jha S, Dhooria A, Naidu GSRSNK, Minz RW, Kumar S, Sharma SK, Sharma A, Jain S, Dhir V. Kumar RR, et al. J Clin Rheumatol. 2019 Dec 28. doi: 10.1097/RHU.0000000000001234. Online ahead of print. J Clin Rheumatol. 2019. PMID: 31895110
BACKGROUND: Antisynthetase syndrome is characterized by a triad of myositis, arthritis, and interstitial lung disease. Anti-Jo-1 is the most common associated autoantibody. This study planned to look at the presentation of anti-Jo-1 antisynthetase syndrome in a sing …
BACKGROUND: Antisynthetase syndrome is characterized by a triad of myositis, arthritis, and interstitial lung disease. Anti-Jo-1 is t …
Anti-Jo-1 antibodies.
Zampieri S, Ghirardello A, Iaccarino L, Tarricone E, Gambari PF, Doria A. Zampieri S, et al. Autoimmunity. 2005 Feb;38(1):73-8. doi: 10.1080/08916930400022640. Autoimmunity. 2005. PMID: 15804708
Anti-Jo-1 antibody is a myositis specific autoantibody most commonly found in patients with idiopathic inflammatory myopathies (IIM). ...Moreover, anti-Jo-1 serum levels strongly correlate with disease activity representing a good marker for disease monitoring....
Anti-Jo-1 antibody is a myositis specific autoantibody most commonly found in patients with idiopathic inflammatory myopathies (IIM). …
The role of Jo-1 in the immunopathogenesis of polymyositis: current hypotheses.
Ascherman DP. Ascherman DP. Curr Rheumatol Rep. 2003 Dec;5(6):425-30. doi: 10.1007/s11926-003-0052-2. Curr Rheumatol Rep. 2003. PMID: 14609486 Review.
Beyond a previously developed animal model that has demonstrated the capacity of Jo-1 to promote humoral and cell-mediated immune responses leading to myositis, recent studies have revealed the existence of Jo-1-specific T cells in the peripheral blood of patients w …
Beyond a previously developed animal model that has demonstrated the capacity of Jo-1 to promote humoral and cell-mediated immune res …
[Antisynthetase syndromes].
Bauhammer J, Fiehn C. Bauhammer J, et al. Z Rheumatol. 2019 Sep;78(7):645-655. doi: 10.1007/s00393-019-0665-0. Z Rheumatol. 2019. PMID: 31346706 Review. German.
Autoantibodies to 11 aminoacyl-tRNA synthetases are known of which 8 have so far been associated with the clinical manifestation of ASS. The Jo-1 antibody is by far the most frequent one. The antibodies differ in the rate and severity of the main and accompanying symptoms. …
Autoantibodies to 11 aminoacyl-tRNA synthetases are known of which 8 have so far been associated with the clinical manifestation of ASS. The …
Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome.
Zamora AC, Hoskote SS, Abascal-Bolado B, White D, Cox CW, Ryu JH, Moua T. Zamora AC, et al. Respir Med. 2016 Sep;118:39-45. doi: 10.1016/j.rmed.2016.07.009. Epub 2016 Jul 16. Respir Med. 2016. PMID: 27578469 Free article. Clinical Trial.
BACKGROUND: Interstitial lung disease (ILD) is a common extra-muscular manifestation of antisynthetase (AS) syndrome. ILD prevalence is higher with anti-Jo-1 antibody positivity. Data on long-term outcomes in these patients are lacking. METHODS: Over 15 years, we identifie …
BACKGROUND: Interstitial lung disease (ILD) is a common extra-muscular manifestation of antisynthetase (AS) syndrome. ILD prevalence is high …
The Jo-1 antibody system in myositis: relationships to clinical features and HLA.
Arnett FC, Hirsch TJ, Bias WB, Nishikai M, Reichlin M. Arnett FC, et al. J Rheumatol. 1981 Nov-Dec;8(6):925-30. J Rheumatol. 1981. PMID: 6977032
Within myositis subgroups, anti-Jo-1 occurred in 6/20 (30%) with polymyositis, 2/16 (13%) with dermatomyositis and 3/7 (43%) with overlap. ...All anti-Jo-1 positive patients had either HLA-DR3, HLA-DRW6 or both (p less than or equal to 0.01). ...
Within myositis subgroups, anti-Jo-1 occurred in 6/20 (30%) with polymyositis, 2/16 (13%) with dermatomyositis and 3/7 (43%) with ove …
20,645 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback